• Cosmos Health entered a non-binding LOI to buy 100% of Doc Pharma, a European GMP pharmaceutical manufacturer.
• Doc Pharma’s three-year average annual revenue was USD 6.7 million, with average annual gross profit of USD 3.2 million.
• The target has an asset base of about USD 24 million, including a GMP-licensed 59,000-square-foot production facility.
• The deal is expected to be immediately accretive, supporting margin expansion, profitability, and cash flow.
• Transaction aims to deepen vertical integration, expand in-house manufacturing capacity, and broaden the product portfolio in generics and OTC drugs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606111531PRIMZONEFULLFEED9745778) on June 11, 2026, and is solely responsible for the information contained therein.